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Abstract
Background: African Americans have a disproportionate prevalence and incidence of type 2 diabetes compared
with Caucasians. Recent evidence indicates that low cardiorespiratory fitness (CRF) level, an independent risk factor
for type 2 diabetes, is also more prevalent in African Americans than Caucasians. Numerous studies in Caucasian
populations suggest that vigorous exercise intensity may promote greater improvements in CRF and other type 2
diabetes risk factors (e.g., reduction of glucose/insulin levels, pulse wave velocity, and body fat) than moderate
intensity. However, current evidence comparing health benefits of different aerobic exercise intensities on type 2
diabetes risk factors in African Americans is negligible. This is clinically important as African Americans have a
greater risk for type 2 diabetes and are less likely to meet public health recommendations for physical activity than
Caucasians. The purpose of the HI-PACE (High-Intensity exercise to Promote Accelerated improvements in
CardiorEspiratory fitness) study is to evaluate whether high-intensity aerobic exercise elicits greater improvements in
CRF, insulin action, and arterial stiffness than moderate-intensity exercise in African Americans.
Methods/Design: A randomized controlled trial will be performed on overweight and obese (body mass index of
25–45 kg/m2) African Americans (35–65 years) (n = 60). Participants will be randomly assigned to moderate-intensity
(MOD-INT) or high-intensity (HIGH-INT) aerobic exercise training or a non-exercise control group (CON) for 24
weeks. Supervised exercise will be performed at a heart rate associated with 45–55% and 70–80% of VO2 max in
the MOD-INT and HIGH-INT groups, respectively, for an exercise dose of 600 metabolic equivalents of task (MET)-
minutes per week (consistent with public health recommendations). The primary outcome is change in CRF.
Secondary outcomes include change in insulin sensitivity (measured via an intravenous glucose tolerance test),
skeletal muscle mitochondrial oxidative capacity (via near-infrared spectroscopy), skeletal muscle measurements (i.e.,
citrate synthase, COX IV, GLUT-4, CPT-1, and PGC1-α), arterial stiffness (via carotid-femoral pulse wave velocity), body
fat, C-reactive protein, and psychological outcomes (quality of life/exercise enjoyment).
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Discussion: The anticipated results of the HI-PACE study will provide vital information on the health effects of
high-intensity exercise in African Americans. This study will advance health disparity research and has the potential
to influence future public health guidelines for physical activity.
Trial registration: ClinicalTrials.gov identifier: NCT02892331. Registered on September 8, 2016.
Keywords: Methodology, Exercise intensity, African American, Cardiorespiratory fitness, Insulin sensitivity, Arterial
stiffness
Background
The American Diabetes Association (ADA) identifies ra-
cial health disparities in type 2 diabetes (T2D) as a major
public health concern [1]. T2D prevalence in African
Americans (AAs) is one of the greatest in the US; AAs
have about 1.7-fold higher rates compared with their
Caucasian American (CA) counterparts (females: 13.6%
versus 7.4%; males: 14.1% versus 8.0%, respectively) [2].
An ADA position statement from 2016 [3] recognized
the importance of physical activity to prevent T2D, as
low levels are associated with greater T2D incidence.
The prevalance of AAs meeting public health recom-
mendations for physical activity is considerably lower
than CA adults (56.5% versus 67.5%, respectively) [4].
Despite established racial disparities in T2D risk, AAs
are under-represented in exercise research (i.e., sample
sizes inadequate for sub-group analyses and few ran-
domized clinical trials specifically examining AAs). This
lack of data critically limits the federal Physical Activity
Guidelines from making accurate conclusions on the ef-
fects of physical activity on health outcomes in AAs [5].
Low cardiorespiratory fitness (CRF) is an independent
risk factor for T2D incidence [6–11]. However, an incre-
mental dose response has been observed between CRF
level and T2D incidence [8, 12]. Categorically defined
“low CRF” is associated with the greatest risk of T2D,
and a greater proportion of AAs have “low CRF” than
CAs [8, 10, 13–27]. Higher intensities of aerobic exercise
show promise in eliciting a larger magnitude of improve-
ment in insulin sensitivity compared with moderate
intensity. Moreover, arterial stiffness, another racial dis-
parity identified in AAs, has shown a greater decline
from high-intensity exercise than moderate intensity
[28–30]. An additional contributor to the T2D racial dis-
parities is the lower oxidative characteristics and subse-
quent reduced insulin sensitivity of skeletal muscle in
AAs compared with CAs [13, 26, 31–33]. AAs tend to
have a greater proportion of type II muscle fibers (i.e.,
less oxidative, vascularized, lower proportion of GLUT-4
transporters, and more insulin-resistant than type I fi-
bers) compared with CAs [32, 34, 35]. A major adapta-
tion to aerobic training is the shift in both type I and II
fibers toward more oxidative properties (e.g., increased
mitochondria size, density, and enzymes) and increased
sensitivity to insulin (increased GLUT-4 expression)
[36, 37]. Thus, lower CRF levels in AAs may contrib-
ute to the racial health disparities in T2D.
Data examining CAs suggest that high-intensity aer-
obic training results in greater improvements in CRF, in-
sulin action, and arterial stiffness compared with
moderate intensity [26, 38, 39]. Thus, high-intensity ex-
ercise may improve the low-CRF, stiffened-artery, and
insulin-resistant disposition observed in obese AAs more
readily because of greater shear rates in the vasculature,
recruitment of type II fibers, and greater energy expend-
iture rates than moderate intensity. There are, however,
no current randomized controlled trials comparing the
health benefits of different exercise intensity training
programs in AAs despite the greater T2D risk in AAs
than CAs.
The goal of the HI-PACE (High-Intensity exercise to
Promote Accelerated improvements in CardiorEspira-
tory fitness) study is to evaluate the effects of exercise
intensity on CRF, insulin action, and arterial stiffness in
AAs at high risk for T2D. The purpose of the following
article is to describe the design, rationale, and method-
ology of the HI-PACE study.
Specific objectives
The objective of the HI-PACE study is to determine
whether high-intensity aerobic exercise training results
in greater improvements in CRF, insulin action, arterial
stiffness, mitochondrial function, adiposity, and quality
of life compared with moderate intensity. Thus, the pri-
mary outcome of the HI-PACE study is the change in
CRF following the intervention. Main secondary out-
comes include change in insulin sensitivity (measured
via an intravenous glucose tolerance test [IVGTT]), skel-
etal muscle mitochondrial oxidative capacity (via near-
infrared spectroscopy [NIRS]), skeletal muscle measure-
ments (i.e., citrate synthase, COX IV, GLUT-4, CPT-1, and
PGC1-α), arterial stiffness (via carotid-femoral pulse wave
velocity [PWV]), body fat, C-reactive protein, and psycho-
logical outcomes (quality of life/exercise enjoyment).
Participants will be randomly assigned to one of three
groups: (1) moderate-intensity (MOD-INT), (2) high-in-
tensity (HIGH-INT), or (3) a non-exercise control
(CON) group for 24 weeks. The exercise volume for
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both exercise groups will be 600 metabolic equivalents
of task (MET)-minutes per week (3–4 sessions per
week), which is consistent with the current public health
guidelines (500–1,000 MET-minutes) [5]. Participants in
the MOD-INT group will exercise at the heart rate asso-
ciated with 45–55% of maximal oxygen consumption
(VO2 max), and participants in the HIGH-INT group
will exercise at the heart rate associated with 70–80%
VO2 max. Fitbit Flex accelerometers (Fitbit Inc., San
Francisco, CA, USA) will be worn on the wrist by partic-
ipants in all randomization groups to objectively moni-
tor non-exercise physical activity during the intervention
(devices will be removed during training sessions).
Methods/Design
Inclusion/exclusion criteria
The main inclusion and exclusion criteria for HI-PACE
are shown in Table 1. The HI-PACE study is designed to
intervene in sedentary, overweight, and obese AAs at
high risk for T2D. Thus, we plan to enroll 60 sedentary,
overweight, and obese AA adults (body mass index
[BMI] of 25.0–45.0 kg/m2 and age of 35–65 years). All
participants will be sedentary/low active and not partici-
pating in exercise training at the time of enrollment (<
20min and ≤2 days per week for the last 3 months).
Major exclusion criteria for the HI-PACE study include
diagnosed type 1 or 2 diabetes (or fasting glucose of
more than 125 mg/dL or use of diabetes medication),
known cardiovascular diseases (e.g., heart failure, serious
arrhythmias, and peripheral vascular disease), previous
stroke or myocardial infarction, excessively high resting
systolic (>180mm Hg) or diastolic (>100mm Hg) blood
pressure, significant medical conditions, life-threatening
conditions, pregnancy or plans to become pregnant, and
other medical conditions that are contraindicated for
exercise training. Additionally, individuals who plan to
diet, engage in weight loss, or demonstrate non-compli-
ance during screening visits will be excluded.
The study protocol has been approved by the East
Carolina University (ECU) institutional review board
and is registered on ClinicalTrials.gov (NCT02892331).
This study protocol was prepared on the basis of the
SPIRIT (Standard Protocol Items: Recommendations for
Interventional Trials) guidelines. This SPIRIT Checklist
is available as Additional file 1.
Recruitment and pre-screening
A detailed summary of the study visits is described in
Table 2. Recruitment material will be disseminated
through newspaper (general readership and an AA-spe-
cific newspaper), targeted social media advertisement (e.g.,
Facebook and Instagram), email sent through company
employee listservs (i.e., ECU, Pitt Community College,
and Greenville government), and local organizational
contacts in the Pitt County, North Carolina area (e.g.,
churches, physician offices, libraries, and barbershops). In
addition, a study website will be created to provide basic
study information and to serve as a mechanism for web-
screening potential participants. Web-screening will be
performed by using an online survey in which basic inclu-
sion/exclusion criteria questions can be completed and
subsequently reviewed by study staff. This online survey is
created by using an online research database, REDCap
(Nashville, TN, USA) [40], which is connected to the main
Table 1 Major inclusion and exclusion criteria
Inclusion criteria
Age 35–65 years




Physically inactive Sedentary/low active, not participating in
regular aerobic or resistance exercise < 20
min, ≤2 days/week for last 3 months
African American Self-identify as African American
Informed consent Willingness and capability to provide written
consent and to understand the exclusion
criteria
Exclusion criteria




Diagnosed congestive heart failure, serious
arrhythmias, peripheral vascular disease with
intermittent claudication, previous stroke, or
myocardial infarction
Resting blood pressure Excessively high resting systolic (>180
mmHg) or diastolic (>100 mmHg) blood
pressure. Participants taking blood pressure
medications at time of recruitment are
permitted to enroll.
Blood lipids Total cholesterol ≥240mg/dL, low-density




Chronic or reoccurring neuromuscular,
respiratory, gastrointestinal, neurological, HIV,
or psychiatric conditions. Musculoskeletal
conditions affecting exercise. Current
treatment for mental illness or hospitalization
from mental illness within previous 5 years.
Autoimmune or collagen vascular diseases.
Other medical conditions that are considered
life-threatening or that can be provoked
from exercise training
Other exclusion criteria Pregnancy or plans to become pregnant.
Currently engaging in or plans to engage in
weight loss or dieting program. Addition of
medication or dosage (or both) unstable in
past 3 months. Previous bariatric surgery or
current weight loss medications. Plans to
leave the Pitt County (NC) area for more
than 2 weeks during the next 6 months.
Non-compliance in wearing pedometer or
demonstration of high risk for non-
compliance/dropout during screening
McGee et al. Trials          (2019) 20:484 Page 3 of 14
study database. Interested individuals can also contact HI-
PACE staff by calling the study phone number or by dir-
ectly emailing the research coordinator. After this, study
staff will phone-screen individuals for major aspects of the
inclusion/exclusion criteria and provide additional infor-
mation about study participation. Individuals who are eli-
gible and still interested after phone screening will
progress to screening visit 1.
Screening visits
Screening visits will be conducted at the East Carolina Heart
Institute by the research coordinator. During screening visit
1, the research coordinator will describe all properties of
study participation, answer questions from individuals, and
obtain informed consent. Following consent, the research
coordinator will screen participants for the full inclusion/ex-
clusion criteria, collect contact/demographic information,
and review prescribed medications (individuals will be re-
quired to bring in prescribed medications for verification).
For inclusion/exclusion purposes, height and weight (with-
out shoes) will be measured to calculate BMI (in kilograms
per square meters), and seated resting blood pressure will be
assessed via an automated blood pressure monitor (HEM-
907XL, Omron Healthcare Co., Ltd., Kyoto, Japan).
Individuals will be screened for ample time to partici-
pate in the exercise intervention by filling out an exer-
cise calendar form, in which they will be asked to
identify specific days and times (and back-up times) they
are available to exercise at our facility (Additional file 2:
Appendix A). Staff will also conduct a standardized
interview with potential participants in which (a) weekly
time commitments, (b) responsibilities for family care
(i.e., child and elder), (c) distances of home and work
from our exercise facility, (d) personal motivations for
exercising, (e) levels of familial support, and (f ) any
other barrier(s) that would affect study adherence will be
evaluated (Additional file 2: Appendix B). The exercise
calendar and interview are intended to screen out indi-
viduals depicting high risk for non-compliance or drop-
out (or both) during the 24-week study. Previous studies
using similar methodologies exhibited high exercise
training adherence and study retention [41, 42].
Individuals who are still eligible at this point will wear
a Fitbit Flex (Fitbit Inc.) and an activPAL accelerometer
(PAL Technologies Ltd., Glasgow, UK) for 7 continuous
days to assess baseline non-exercise physical activity
level. The Fitbit Flex will be worn on the non-dominant
wrist to obtain data on steps, miles, intensity, and calorie
expenditure each day of wear (blinded to individual).
Study staff will apply the activPAL by rolling a nitrile
sleeve over the entire device and wrap an 8 × 10 cm
sheet of transparent medical dressing completely around
it to act as a waterproof barrier. Staff will rub an alco-
hol-based prep pad around the site, place the distal end
of the activPAL toward the knee, and apply a separate
sheet of medical dressing over the monitor to complete
application to the leg (waterproofing method). The activ-
PAL accelerometer will be worn on the individual’s mid-
thigh and will not be removed for the entire 7 days. The
activPAL measures postural aspects of time spent sitting/
lying down, standing, and walking in hours per day as well
as energy expenditure (MET-hours per day), steps per day,
and number of sit-to-stand transitions.
The HI-PACE study will use a REDCap database to
store all information collected from screening visits (e.g.,
contact/demographic information and blood lab results)
and to track physical activity data during the physical ac-
tivity assessment. During each day the devices are worn,
REDCap surveys will be sent automatically to individuals’
email address to ask whether the activPAL and Fitbit de-
vices were worn on the previous day and whether there
Table 2 Detailed summary of data collection at study visits
Screening visit and informed consent
- Informational session about study requirements
- Obtain informed consent
- Verify inclusion criteria (i.e., BMI and blood pressure)
- Physical exam/review of medications
- Non-exercise physical activity via activPAL
- Exercise calendar and Barriers screening forms
- Complete metabolic panel, lipids, insulin, C-reactive protein, and
blood chemistries
Baseline
- PWV, muscle biopsy, IVGTT, and NIRS
- SF-36 and FFQ
- Body weight, blood pressure, anthropometry, DEXA, and maximal
exercise test
Randomization




- Maximal exercise test
Follow-up (24 weeks)
- Non-exercise physical activity via activPAL
- PWV, muscle biopsy, IVGTT, and NIRS
- SF-36 and FFQ
- Complete metabolic panel, lipids, insulin, C-reactive protein, and
blood chemistries
- Body weight, blood pressure, anthropometry, DEXA, and maximal
exercise test
Abbreviations: BMI body mass index, CON non-exercise control (group), DEXA
dual-energy x-ray absorptiometry, FFQ food frequency questionnaire, HIGH-INT
high-intensity exercise (group), IVGTT intravenous glucose tolerance test, MOD-
INT moderate-intensity exercise (group), NIRS near-infrared spectroscopy, PWV
pulse wave velocity, SF-36 short-form health survey
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were any extended periods of non-wear time. The purposes
of the survey are to (1) increase the accuracy of the physical
activity assessment by being able to eliminate days affected
by non-wear and (2) prompt individuals to wear the devices
consistently. Since changes in non-exercise physical activity
can confound exercise-related changes in outcome mea-
sures [43, 44], it is necessary to ensure that participants in
the HI-PACE study can regularly wear the devices.
Following completion of the baseline physical activity as-
sessment (7 days), individuals will return in the fasted state
to the East Carolina Heart Institute for screening visit 2 in
the morning. The study nurse will perform a fasting blood
draw and immediately send the sample to a clinical labora-
tory (LabCorp Inc., Burlington, NC, USA) for complete
metabolic panel, lipid panel, insulin level, and blood chemis-
tries. Pre-menopausal women will be required to complete a
pregnancy test. The Fitbit and activPAL will be retrieved for
accelerometer data to be downloaded and recorded in the
study database. Upon completion of the screening visits, in-
dividuals will be scheduled for the baseline assessment visit.
Assessment visits (baseline, mid-intervention, and follow-up)
A flowchart of the present study is shown in Fig. 1. Pri-
mary (i.e., CRF) and secondary outcome measures (i.e., ar-
terial stiffness, mitochondrial measures, insulin sensitivity,
skeletal muscle oxidative capacity, quality of life, and
food-frequency questionnaires [FFQ]) will be obtained at
baseline and follow-up (week 24). At mid-intervention
(week 12), CRF, resting blood pressures, and anthropom-
etry (i.e., body mass, waist circumference, and BMI) will
be re-evaluated. Measurements of arterial stiffness, muscle
biopsy, IVGTT, and NIRS will be obtained in this order
during the same visit (baseline and follow-up), whereas
CRF, anthropometry, and body composition will be
obtained during the same visit of a separate week. The pri-
mary outcome will be obtained at the Human Perform-
ance Laboratory in the Ward Sports Medicine Building,
whereas the secondary outcomes will be obtained at the
East Carolina Heart Institute. Randomization into a study
group will occur upon completion of all baseline assess-
ments. For an overview of the schedule of enrollment,
randomization, intervention, and assessments, see Fig. 2
for the completed SPIRIT figure.
Primary outcome: change in maximal oxygen uptake
(VO2 max)
The primary outcome measurement is CRF due to the
well-established association between CRF levels and risk
of T2D [8, 10, 11, 27]. We will measure CRF as VO2 max
(the gold standard) from a maximal exertion treadmill test
under the supervision of a physician. Maximal exercise
testing will be conducted on a treadmill (Cardiac Science
TM65, Davis Medical Electronics, Bothell, WA, USA)
under a modified Balke protocol. For the warm-up,
Fig. 1 Flowchart of study visits in the HI-PACE (High-Intensity exercise to Promote Accelerated improvements in CardiorEspiratory fitness) study
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participants will initially walk at a speed of 2.0 mph at 0%
grade for 2min. Subsequently, we will increase treadmill
speed to 3.0 mph to begin the treadmill test. During the
test, we will increase the treadmill grade by 2.5% every 2
min until volitional exhaustion. Gas exchange (i.e., VO2
and carbon dioxide production (VCO2)) and pulmonary
ventilation will be measured continuously by using a
TrueOne 2400 Metabolic Measurement Cart (Parvo
Medics, Salt Lake City, UT, USA). Heart rate, blood pres-
sure, rating of perceived exertion, and electrocardiogram
will be monitored and recorded before, during, and after
the exercise test. The electrocardiogram will be cleared by
the study physician prior to participant randomization. A
valid maximal exercise test will meet two of three end cri-
teria: (1) elevated respiratory exchange ratio (RER)
(≥1.10), (2) plateauing of VO2, or (3) within ± 5 beats per
minute of age-predicted maximal heart rate.
Secondary outcome measures
Secondary outcome measures include change in insulin
action, arterial stiffness, mitochondrial function, body
fat, C-reactive protein, and psychological surveys.
Insulin sensitivity
Insulin sensitivity will be assessed at baseline and follow-
up (24 h following the last exercise session for the
MOD-INT and HIGH-INT groups) via an IVGTT. After
collection of fasting blood samples, glucose (dextrose
50%) will be injected into a catheter placed in the ante-
cubital vein at a dose of 0.3 g/kg body weight. Subse-
quently, blood samples will be obtained at the following
time points: 2, 3, 4, 5, 6, 8, 10, 12, 14, 16, 19, 22, 25, 30,
40, 50, 60, 70, 80, 90, 100, 120, 140, 160, and 180 min.
Insulin will be injected at minute 20 of the test at a dose
of 0.025 U/kg body weight. Blood samples will be
centrifuged and stored at −80 °C until sample analysis
for glucose and insulin. Insulin sensitivity index will be
determined through a minimal model [45]. Follow-up
IVGTT will be assessed within 18–24 h of the MOD-
INT and HIGH-INT participants’ last exercise session.
Arterial stiffness
Carotid-femoral PWV and aortic blood pressure parame-
ters will be measured by using a SphygmoCor XCEL
(AtCor Medical, Itasca, IL, USA). Carotid-femoral PWV,
an index of the degree of arterial stiffness, is the gold-
standard measurement of arterial stiffness [46]. Arterial
stiffness measurements will occur during the morning in
a quiet, temperature-controlled room at baseline and fol-
low-up. Prior to each measure, participants will refrain
from vigorous exercise, tobacco, caffeine, and alcohol for
at least 12 h as well as large meals for at least 6 h. Partic-
ipants will take their prescribed medications which will
be logged and repeated at follow-up. The methodology
for arterial stiffness measurements will adhere to a pos-
ition stand by the American Heart Association [47].
For aortic blood pressure and stiffness measurements,
participants will be in the seated position for a 5-min
rest period. Following rest, aortic blood pressure (e.g.,
brachial blood pressures and aortic blood pressures) and
stiffness (e.g., augmentation index and wave reflection)
parameters will be obtained on the basis of acquisition
of brachial artery pressure waveforms with the applica-
tion of a generalized transfer function to derive the cen-
tral aortic pressure waveform, from which estimates of
aortic blood pressures are generated. Three measure-
ments will be performed for aortic blood pressure pa-
rameters with a 1-min rest period between each
measurement.
Fig. 2 Study schedule of enrollment, intervention, and assessments. Abbreviations: AIx augmentation index, CON non-exercise control group, DEXA
dual-energy x-ray absorptiometry, FFQ food frequency questionnaire, HIGH-INT high-intensity exercise group, IVGTT intravenous glucose tolerance
test, MOD-INT moderate-intensity exercise group, NIRS near-infrared spectroscopy, PA physical activity, PWV pulse wave velocity, SF-36 short-form
health survey, t1 baseline, t2 mid-intervention (week 12), t3 follow-up (week 24)
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Subsequently, PWV will be obtained in the supine
position following a 15-min rest. During rest, body sur-
face measurements will be measured via a Gulick tape
measure (Baseline, Fabrication Enterprises, White Plains,
NY, USA) in triplicate to determine the distance traveled
by the pulse wave between the carotid and femoral ar-
tery sites. Study staff will palpate and mark the carotid
artery pulse (between the larynx and sternocleidomas-
toid muscle in the neck), the sternal notch (superficial
landmark of aortic arch), and femoral artery pulse (over
the ventral thigh halfway between the pubic symphysis
and anterior superior iliac spine) [48]. The mean dis-
tance for each site will be used for PWV calculation.
Pressure waveforms at the carotid arterial site will be ac-
quired via applanation tonometry and electrocardio-
graphic gating and the femoral arterial site will be
simultaneously acquired by using the oscillometric de-
vice within the SphygmoCor XCEL. The PWV measure-
ment will be conducted in duplicate, and the mean of
these measurements will be the reported value. Both
measurements must be within 0.5 m per second to be
considered acceptable for data purposes. If the two mea-
surements differ by more than 0.5 m per second, a third
measurement will be obtained, and the reported value
will be the median of the three measurements.
Mitochondrial function
A percutaneous muscle biopsy (100–200 mg of tissue)
will be obtained by using sterile techniques at baseline
and follow-up from the vastus lateralis with a 5-mm
Bergström muscle biopsy cannula with suction (Stille
Surgical Instruments, Eskilstuna, Sweden), as previously
described [49]. Briefly, participants will lie supine with
legs extended (0° flexion) and two operators will spray
ethyl chloride on the biopsy site and administer 1% lido-
caine at each level of subcutaneous tissue, stopping
superficial to the fascia. Following 2–3 min to allow for
the local anesthetic effects, a 1-cm incision will be made
through the skin and subcutaneous tissues, parallel to
the femur, until an incision is made through the muscle
fascia. The operator will use the biopsy cannula to locate
the fascia incision site and advance the needle past the
fascia, angled downward toward the floor to rapidly clip
and collect the muscle sample with suction by the sec-
ond operator. Following the biopsy, the sample will be
trimmed of visible adipose tissue, weighed on a scale
(AL54, Mettler-Toledo, Columbus, OH, USA), and snap-
frozen in liquid nitrogen to be stored at −80 °C until
analysis at study completion.
Peroxisome proliferator-activated receptor gamma co-
activator 1-alpha (PGC1-α), COX IV, GLUT-4, and
CPT-1 content will be determined; these proteins were
selected as they are downstream of PGC1-α and repre-
sent distinct steps in oxidative metabolism [50]. About
50mg of muscle tissue will be homogenized (T8 Ultra
Turrax; IKA, Wilmington, NC, USA) in 20 volumes of
cell lysis buffer (50 mM HEPES, 12 mM sodium pyro-
phosphate, 100 mM sodium fluoride, 100 mM ethylene-
diaminetetraacetic acid, 10 mM sodium orthovanate, 1%
Triton X-100) supplemented with a protease and phos-
phatase inhibitor cocktails (Sigma-Aldrich, St. Louis,
MO, USA). Lysates will be sonicated for 5 s, rotated for
about 1 h at 4 °C, and centrifuged at 13,500 × g for 15
min at 4 °C. Protein concentration for each sample hom-
ogenate will be determined via a commercially available
bicinchoninic acid protein assay kit (Pierce, Rockford,
IL, USA). Aliquots containing 30 μg of total protein will
be diluted in 4x Laemmli Buffer (Bio-Rad Laboratories,
Inc., Hercules, CA, USA) with 5% β-mercaptoethanol
(βME) at a 3:1 ratio prior to heating at 70 °C for 10min.
Denatured samples will be brought to room temperature,
loaded onto a 10% polyacrylamide gel, separated by SDS-
PAGE, and transferred to nitrocellulose membranes.
Membranes will be blocked with Odyssey Blocking Buffer
(OBB; Li-Cor, Lincoln, NE, USA) for 1 h and incubated
with primary antibodies. Membranes will be washed with
TBST (Tris-buffered saline, 0.1% Tween 20) and incu-
bated with an anti-rabbit or anti-mouse fluorophore-con-
jugated secondary antibody (1:20,000; Li-Cor) in OBB
supplemented with 0.1% Tween-20 for 1 h. Then the
membranes will be washed with TBST followed by TBS
prior to being scanned on the Odyssey CLx Imaging Sys-
tem (Li-Cor) and quantified on Image Studio software
(V4.0.21; Li-Cor). GAPDH will be used as a loading
control.
Citrate synthase activity will be determined with a col-
orimetric reaction by using reagents in a commercial kit
(Sigma CD0720), as in a previous study [51]. A 10- to
15-mg piece of muscle will be diluted 20-fold in a buffer
containing 100mM KH2PO4 and 0.05% bovine serum al-
bumin and homogenized at 4 °C by using the Ultra Tur-
rax. Homogenates will undergo four freeze-thaw cycles
before experimentation. Protein content will be mea-
sured by using the bicinchoninic acid assay, and citrate
synthase activity will be assessed with reagents provided
in the commercial kit (Sigma CS0720), which uses a col-
orimetric reaction to measure the reaction rate of acetyl
coenzyme A and oxaloacetic acid.
In vivo skeletal muscle mitochondrial oxidative capacity
As an additional measure of mitochondrial function, in
vivo skeletal muscle mitochondrial oxidative capacity
will be measured non-invasively via NIRS at baseline
and follow-up. This NIRS approach measures the recov-
ery kinetics of skeletal muscle oxygen consumption
(mVO2) following brief exercise and has demonstrated
strong correlations with current in vivo and ex vivo
gold-standard measurements of mitochondrial function
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(i.e., magnetic resonance spectroscopy and muscle bi-
opsy) [52, 53]. We will implement a NIRS testing
protocol similar to that of Ryan et al. [53]. NIRS data
will be obtained by using an OxiplexTS (ISS, Cham-
paign, IL, USA), a frequency-domain tissue oximeter.
Briefly, the OxiplexTS is equipped with two independ-
ent data acquisition channels and eight infrared diode
lasers (four emitting at 691 nm and four at 830 nm)
and a detector within each (emitter-detector distances
of 2.0–4.0 cm). The absolute values of oxygenated
hemoglobin (O2Hb) and deoxygenated hemoglobin
(HHb) will be calculated in micromoles in accordance
with the instructions of the manufacturer. Data will
be collected at 4 Hz. Both NIRS probes will be cali-
brated prior to each test by using a phantom with
known optical properties once the device warms up
for at least 20 min.
For each NIRS measurement, participants will be su-
pine on a padded table and have both legs extended (0°
flexion). A skinfold caliper (Lange, Beta Technology,
Santa Cruz, CA, USA) will be used to measure subcuta-
neous adipose tissue thickness at the probe site (about
10 cm above the patella). The NIRS probe will be se-
cured to the skin at the vastus lateralis site with double-
sided adhesive tape and Velcro straps. Additionally, a
blood pressure cuff (Hokanson SC-10D or SC-10 L, D.E.
Hokanson, Inc., Bellevue, WA, USA) will be placed
proximal to the NIRS probe as high as anatomically pos-
sible to prevent unwanted signal noise from cuff infla-
tion. A 15-gal air compressor (Model D55168, Dewalt,
Baltimore, MD, USA) set to 30 psi will power a rapid-in-
flation system (Hokanson E20, D.E. Hokanson) to con-
trol the blood pressure cuff.
Upon securement of the probe and cuff, participants
will complete a short-duration (about 10–30 s), sub-
maximal, repeated knee extension or isometric quadri-
cep exercise (or both) to increase mVO2. Following
exercise, the recovery kinetics of mVO2 will be deter-
mined from a series of repeated arterial occlusions
(275–300 mm Hg) for about 5–7 min in duration by
using the following inflation/deflation timing: 5 s in-
flated/5 s deflated for about 90 s and then 10 s inflated/
10 s deflated for the remainder of test. The beginning
and end of each occlusion will be marked for calcula-
tions of mVO2 from the deoxygenated hemoglobin/
myoglobin signal (i.e., slope during occlusion). The
post-exercise mVO2 data will be fit to a mono-expo-
nential function to calculate the rate constant, which is
directly related to the mitochondrial respiratory cap-
acity [52]. Three trials of exercise and occlusion proce-
dures will be performed and the results will be
averaged. Baseline and follow-up NIRS data will be ana-
lyzed via custom-written routines in MATLAB R2017b
(MathWorks, Natick, MA, USA).
Blood sample collection
A venous blood sample will be drawn with a 21-gauge
needle with the participant in the fasted state at baseline
and follow-up. A total of 21 mL of blood will be drawn
by the study nurse and will immediately be sent to a
clinical laboratory (LabCorp Inc.) for a complete meta-
bolic panel, lipid panel, insulin level, and blood chemis-
tries. Prior to glucose injection during the baseline and
follow-up IVGTT, we will collect vials of archive plasma,
serum, and red blood cells to be stored at −80 °C for fu-
ture analysis. We also will send an additional serum sep-
arator tube to LabCorp Inc. for measurement of C-
reactive protein.
Anthropometry and body composition
Body weight will be measured in the fasted state via a
calibrated scale (DigiTol 8510, Mettler-Toledo) (re-
corded to the nearest tenth of a kilogram). Dual energy
x-ray absorptiometry (GE Lunar Prodigy Advance, Fair-
field, CT, USA) will be used to measure body compos-
ition (fat and fat-free mass) at baseline and follow-up.
Waist circumference will be measured via a Gulick tape
measure at the natural waist (halfway point from the in-
ferior border of the rib cage and the superior point of
the iliac crest). Participants will be instructed to stand
straight and upright with their feet together and arms to
their side. Study staff will mark each landmark and
measure the distance to determine the proper measure-
ment site. For each measure, study staff will confirm that
(1) the tape is parallel to the floor, (2) the tape touches
the entire circumference of the participant, (3) the tape
is not compressing any abdominal tissue, (4) the tape is
not within abdominal folds, and (5) the measurement is
recorded following a normal exhalation by the partici-
pant. Duplicate waist circumference measurements will
be obtained. If measurements are ± 0.5 cm, the reported
value will be the average of the two. If measurements
differ more than 0.5 cm, a third measurement will be
assessed, and the reported value will be the average of
the three measurements. Waist circumference will be
evaluated at baseline, mid-intervention, and follow-up.
Non-exercise physical activity levels
Non-exercise physical activity data will be monitored in
all randomization groups by using a Fitbit Flex activity
tracker throughout the intervention period. Each group
will be blinded to the number of steps accrued and
instructed not to change their non-exercise physical ac-
tivity levels from baseline. Prior to each exercise session,
the Fitbit device will be removed from the participant
(to not mix exercise and non-exercise physical activity
data) and synced to the Fitbit software to upload their
non-exercise physical activity levels. Participants in the
CON group will sync their data at home by using the
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Fitbit software and be monitored by study staff to ensure
compliance. Automated REDCap surveys will be emailed
three times per week to all participants to inquire about
Fitbit wear. Participants will be instructed to fill out
these surveys to validate consistent device wear as this
will allow staff to input non-exercise physical activity
data on a weekly basis. This process helps to ensure con-
sistent daily wearing of the device and to determine
whether the participant did not wear the Fitbit for ex-
tended periods of time.
Study staff will use a database program (Fitabase,
Small Steps Labs, San Diego, CA, USA) to centralize all
non-exercise physical activity data (i.e., total daily steps,
minutes of light, moderate and vigorous physical activity,
miles traveled, and estimated kilocalorie energy expend-
iture). All non-exercise physical activity data synced to
Fitabase will be stored in a custom-made REDCap data-
base. Study staff will input all non-exercise physical ac-
tivity data on a weekly basis.
Dietary composition
Dietary intake will be tracked at baseline and follow-up
via the Block FFQ [54]. The FFQ consists of 105 catego-
rized items and assesses both frequency of consumption
and portion size selections, in which participants will re-
call their typical eating habits within the previous 3
months at baseline and follow-up time points. The ques-
tionnaire estimates daily intake values of kilocalories and
select macronutrients and micronutrients and also cal-
culates servings by food group. The research coordinator
will instruct participants at screening visit 1 to maintain
current dietary habits and not to begin intentional diet-
ing for the entirety of the study. Additionally, study staff
will remind all participants on a weekly basis not to change
their eating habits during the intervention. The FFQ serves
as a semi-quantitative measure to ensure that dietary habits
are not changed throughout the intervention.
Psychological parameters
The short form health survey (SF-36) [55] will be used
to measure quality of life at both baseline and follow-up.
Exercise enjoyment will be assessed via the Physical Ac-
tivity Enjoyment (PACE) Scale [56] and the Feeling Scale
[57]. As secondary outcomes, the impact of exercise in-
tensity on these affective responses (i.e., feelings of
overall pleasure/displeasure and enjoyment) plays an im-
portant role in physical activity participation and adher-
ence [58–60]. The PACE Scale is composed of eight
items rated on a 7-point semantic differential scale in
which “4” represents a neutral position. The PACE Scale
will be collected every 4 weeks during the exercise inter-
vention. Affective responses to exercise will be assessed
by having participants complete the Feeling Scale. The
Feeling Scale is a single-item, 11-point scale that assesses
how individuals feel at a specific moment in time. The
scale ranges from −5 (very bad) to +5 (very good), and 0
represents neutral feelings. Study staff will collect Feel-
ing Scale data every 5 min during the first exercise ses-
sion of every week of the exercise intervention.
Randomization
Participants will be randomly assigned to the non-exer-
cise control (CON), moderate-intensity (MOD-INT), or
high-intensity (HIGH-INT) group upon completion of
all baseline assessments and approval by the study phys-
ician. The study biostatistician will generate a
randomization list to allocate participants in a 1:1:1 ratio
to study groups. The randomization process will be per-
formed by an individual separate from the research
team, who has no interaction with the study participants
or access to HI-PACE study data. All other research staff
(including the principal investigator) will not have access
to the randomization list. Once a participant has com-
pleted all baseline assessments, study staff will email the
participant’s identification number and gender to the in-
dividual. The participant will be assigned to the next
group on the randomization list. Upon randomization,
the intervention period will begin the following week. A
study flowchart is shown in Fig. 1.
Aerobic exercise training
All exercise sessions will be supervised by study staff
and performed on a treadmill (Precor TRM 885, Precor
Inc., Woodinville, WA, USA) to sustain control of en-
ergy expenditure from exercise. Participants in the
MOD-INT group will exercise at a target heart rate asso-
ciated with 45–55% VO2 max, and participants in the
HIGH-INT group will exercise at a target heart rate as-
sociated with 70–80% VO2 max. The heart rate range
for each participant will be determined on the basis of
the maximal exercise test (baseline and mid-interven-
tion). The full exercise dose for both groups will be 600
MET-minutes per week, which is consistent with current
public health guidelines [5]. Since participants will be
sedentary at baseline, we will increase the exercise dose
incrementally throughout the study to avoid potential
adverse events during exercise. Initially, the exercise
dose will be 300 MET-minutes during week 1 and will
increase by 50 MET-minutes per week until the max-
imum exercise volume of 600 MET-minutes is reached
at week 9. The exercise dose will remain at 600 MET-
minutes until conclusion of the intervention (Fig. 3). We
will calculate the number of MET-minutes exercised on
the basis of treadmill speed/grade and the participants’
weight by using the standard American College of Sports
Medicine (ACSM) walking equation [61]. Custom-made
Excel spreadsheets will be used to determine exercise
time for each session on the basis of (1) the required
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weekly MET-minutes, (2) the participants’ weight, (3) ex-
ercise speed/grade, and (4) the amount of expected ses-
sions per week (3–4 sessions per week).
At the first exercise session of each week, study staff
will weigh participants (without shoes) on a calibrated
scale and remind them not to alter their diet or engage
in an exercise program outside of the study. Addition-
ally, we will ask participants about any changes to their
prescribed medications on a weekly basis.
Prior to starting exercise, participants will rest for 5
min in the seated position, after which study staff will
measure systolic/diastolic blood pressures by using a
Fig. 3 Ramping protocol of required MET-minutes in both the MOD-INT and HIGH-INT groups in the HI-PACE study. Abbreviations: HIGH-INT high-
intensity exercise group, HI-PACE High-Intensity exercise to Promote Accelerated improvements in CardiorEspiratory fitness, MET Metabolic
equivalents of task, MOD-INT moderate-intensity exercise group
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mercury sphygmomanometer and record resting heart
rate via a Zephyr Bioharness 3 monitor (Medtronic, An-
napolis, MD, USA). Each participant will be instructed to
complete a 5-min warm-up on the treadmill at a low
speed (about 2.0 miles per hour) at 0% grade. Following
completion of the warm-up, participants will begin their
prescribed exercise by adjusting the treadmill’s speed or
grade or both. During the supervised exercise, heart rate
will be monitored continuously by using the Bioharness
monitor to confirm exercise intensity and participants will
be required to remain within their target heart range
(MOD-INT: heart rate associated with 45–55% VO2 max;
HIGH-INT: heart rate associated with 70–80% VO2 max).
Heart rate, along with participants’ subjective rating of
perceived exertion (RPE) via the Borg scale, will be re-
corded every 5min [62]. The Feeling Scale will also be re-
corded every 5min on the first exercise session of each
week. Study staff will keep mobile laptop carts nearby the
exercising participant(s) and will use custom-made Excel
spreadsheets to quantify (1) the number of MET-minutes
accumulated during exercise and number of MET-mi-
nutes remaining in the session and (2) mean heart rate
and RPE of the session and (3) calculate the amount of
time remaining in the current session. The spreadsheet
calculates these variables in real time and can compensate
for potential adjustments, such as increasing or decreasing
treadmill speed or grade or both, during the exercise
session.
Once completed with the exercise session, participants
will perform a 5-min cool-down at a similar intensity as
the warm-up. Subsequently, participants will rest for 5
min in the seated position for recording of post-exercise
heart rate and systolic/diastolic blood pressures. Lastly,
study staff will input all exercise session data (i.e., total
exercise duration, MET-minutes, caloric expenditure,
miles traveled, average speed, grade, heart rate, RPE, and
percentage of time participant exercised within target
heart rate range) into the database.
For each exercise session, the mean heart rate will be
calculated by using Omnisense Analysis version 5.0 soft-
ware (Medtronic). The Bioharness monitors continu-
ously record heart rate data on a second-by-second
basis. Thus, to collect the mean heart rate for each ses-
sion, study staff will analyze heart rate data only during
exercise by creating a time-specific sub-session annota-
tion within the Omnisense software to exclude non-ex-
ercise heart rate data from calculation. This process will
more accurately calculate exercise intensities during
training sessions since heart rate will be measured con-
tinuously as opposed to intervals (e.g., every 5 min).
Exercise economy
To address potential variability in exercise economy at a
given workload, study staff will directly measure energy
expenditure (EE) rate via indirect calorimetry (TrueOne
2400) at the participant’s prescribed exercise speed and
grade on a treadmill [42, 63, 64]. This exercise economy
test will be performed on weeks 1, 3, and 5 and then
monthly until the conclusion of the intervention. The
rate of EE determined through indirect calorimetry will
be divided by estimated EE determined from the ACSM
walking equation to develop a correction factor (i.e., ac-
tual EE rate/predicted EE rate). This correction factor
will be used to (1) adjust the EE calculated from the
ACSM equation to more accurately implement the exer-
cise prescription which corresponds to 600 MET-minutes
per week, (2) adjust participants’ exercise session time ac-
cording to potential changes in metabolic or biomechan-
ical efficiency (or both) from exercise training, and (3)
verify required MET-minutes exercised by increasing or
decreasing exercise session time accordingly.
Training data management
Exercise volume adherence will be defined as MET-mi-
nutes exercised divided by required MET-minutes. Exer-
cise intensity adherence will be quantified as time within
the required target heart rate range divided by total exer-
cise time. Exercise compliance will be defined as the num-
ber of sessions attended divided by the number of sessions
required. The research team will actively monitor exercise
volume/intensity adherence, compliance, and other indi-
cators of intervention fidelity (e.g., target heart rate com-
pliance, wear rate of accelerometer, participant morale,
and progression rate of speed/grade) on a weekly basis in
study meetings. In all randomization groups, Fitbit wear
compliance will be monitored throughout the 6-month
intervention. Weekly reports will be compiled from the
study databases to monitor and review the compliance
and adherence rates of all participants.
Statistical considerations
The results of the current pilot study will be used to ad-
vise the design (effect size/statistical power) of a larger
prospective intervention. The response variable for the
primary outcome is change in VO2 max. The three treat-
ment groups—CON, MOD-INT, and HIGH-INT—will
be compared in terms of baseline VO2 max by using
side-by-side boxplots and the corresponding numeric
summaries along with mean and standard deviation.
This will be repeated for post-treatment values of VO2
max and for VO2 max differences of post-treatment and
baseline. If there are distributional concerns, log trans-
formation of VO2 max will be considered. Unless there
are extreme outliers or severe heteroscedasticity, one-
way analysis of variance (ANOVA) will be used for infer-
ence regarding the primary outcome. The two-sample t
test (without assuming equal variances) along with the
associated confidence intervals will be used for
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differences in group means; confidence intervals for dif-
ferences in group means obtained from the one-way
ANOVA will also be reported.
The above steps used for VO2 max (the primary out-
come) will be repeated for each of the numeric variables
used for secondary outcomes. These variables are change
in insulin sensitivity, mitochondrial protein content, cit-
rate synthase activity, skeletal muscle mitochondrial oxi-
dative capacity, arterial stiffness parameters, body fat
percentage, and C-reactive protein. Data will be analyzed
on an intention-to-treat basis.
The ordinal variables of exercise enjoyment and qual-
ity of life will be dichotomized into “no improvement”
and “improvement”. Fisher’s exact test will be used to
obtain an overall P value, and restriction to two of the
treatment groups will provide estimated odds ratios and
the associated confidence intervals.
The three groups will be compared by using the follow-
ing demographic and other variables that may be related
to exercise, change in VO2 max, or one of the other re-
sponse variables: age, sex, body weight, BMI, waist cir-
cumference, body fat percentage, fat mass, fat-free mass,
cholesterol, triglycerides, and blood pressures. If differ-
ences among the treatment groups in terms of one or
more of these variables are deemed important, adjust-
ments to the above comparisons will be made by using
higher-order ANOVA, analysis of covariance (ANCOVA),
or linear regression or a combination of these.
Power ranges from 0.85 for 15 participants per group
to 0.96 for 20 participants per group using −0.112, 0.124,
and 0.200 L/min as the means for the three groups on
the basis of previous data [65], a common standard devi-
ation of 0.250 L/min, and significance level α = 0.05. We
expect attrition to be about 10–15% and so enrollment
of 60 participants (20 per group) will be sufficient for
the primary outcome.
All statistical analyses will be performed by using stat-
istical software in R version 3.5.1. [66]. The resultant
mean change and standard deviation of the change of
outcome measures (if indicative of enhance cardiometa-
bolic improvements in the HIGH-INT compared with
the MOD-INT and CON groups) will be used for power
calculations to determine the necessary sample size of a
larger study.
Discussion
The HI-PACE study has high public health relevance
due to the increased disease burden of T2D and the lack
of exercise training studies in AAs. HI-PACE will be the
first study to compare two exercise training programs
on multiple T2D and cardiovascular risk factors in over-
weight and obese AAs. HI-PACE has the potential to in-
fluence future physical activity recommendations and
advance health disparity research. Additionally, valuable
psychological parameters of quality of life and enjoyment
of exercise will be obtained, which will help determine
whether high-intensity aerobic exercise is a feasible
strategy over a 6-month period to improve health out-
comes in AAs. We anticipate that the results of the HI-
PACE study will provide clear evidence of health bene-
fits from high-intensity exercise, successful recruitment
tactics, and favorable exercise adherence data in at-risk
AAs. The pilot data will be necessary to conduct a lar-
ger-sample-sized exercise intensity study in AAs with
adequately powered primary and secondary variables.
Trial status
Participant recruitment for this study began in Novem-
ber 2016 and is ongoing. The study recruitment is ex-
pected to end in October 2019.
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